Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04821622 · ClinicalTrials.gov registry record · Phase 3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
A Phase 3 study of Prostate Cancer, sponsored by Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 599
- Enrollment target
- 20
- Study locations
NCT04821622 is a Phase 3 study of Prostate Cancer that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 599 participants, roughly in line with the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target. The trial reports 20 study locations across 8 states.
The verdict
NCT04821622, a Phase 3 study of Prostate Cancer, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 599 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.
Conditions Studied
Interventions
- DRUG talazoparib plus enzalutamide
- DRUG Placebo plus enzalutamide
Study Locations (20)
Georgia
- Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital - Austell
- Wellstar Cobb Hospital - Austell
- Northwest Georgia Oncology Centers, a Service of Tanner Medical Center Villa Rica - Carrollton
- West Georgia Infusion Center, a Service of Tanner Medical Center Villa Rica - Carrollton
- Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital - Cartersville
- Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital - Douglasville
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital - Marietta
California
- Beverly Hills Cancer Center - Beverly Hills
- Adventist Health Glendale - Glendale
- VA Long Beach Healthcare System - Long Beach
Alabama
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham - Birmingham
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
- Washington Cancer Institute at MedStar Washington Hospital Center - Washington D.C.
Florida
- AdventHealth Medical Group Hematology and Oncology - Orlando
- Investigational Drug Services, Advent Health Orlando - Orlando
Illinois
- Comprehensive Urologic Care, SC - Lake Barrington
- Mid-Illinois Hematology & Oncology Associates, Ltd - Normal
Arizona
- Arizona Institute of Urology, PLLC - Tucson
Connecticut
- Yale-New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2021-05-12 |
| Est. Completion | 2027-08-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04821622
The ClinicalTrials.gov registry entry for NCT04821622 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 599 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which talazoparib plus enzalutamide is the first listed.
NCT04821622 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Georgia, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT04821622 about?
NCT04821622 is a clinical study titled "Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC". The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.
What is the current status of trial NCT04821622?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 599 participants. The study started on 2021-05-12. Estimated completion is 2027-08-28.
What conditions does trial NCT04821622 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT04821622?
The interventions under investigation include: talazoparib plus enzalutamide (DRUG), Placebo plus enzalutamide (DRUG).
Who is sponsoring clinical trial NCT04821622?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04821622 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.